Adaptive Biotechnologies Corp
ADPTQ2 2022(ADPT Q1 FY2022)Estimated10% AI
AI Revenue %
10%
AI Fair Value
$87.9M
AI Revenue (Q)
$3.9M
Total Revenue (Q)
$38.6M
Source: SEC EDGAR 10-K Filing
View 10-K on SEC.govAnalysis
ADPT operated as a single segment in 2022. Revenue of $38.6M. The company's Immune Medicine business (immunosequencing, Genentech collaboration) used AI/ML for TCR-Antigen mapping, but no segment breakout available. Based on later segment disclosures showing Immune Medicine at ~15-25% of revenue, and applying 50% AI attribution to IM (since AI/ML is an enabling tool within broader sequencing/discovery services, not the sole product), estimated ~10% total AI revenue. MRD/clonoSEQ is NGS-based diagnostics, not AI. Conservative bias: sequencing services are the core deliverable even in the IM segment.
Analyzed by claude-opus-4-6
Quoted Figures
Revenue $38,620K for Q1 2022 (single segment reporting)
10-Q filed 2023-05-10, Income Statement comparative
Our immune medicine platform...underpinned by computational biology and machine learning
10-K filed 2023-02-27, Item 1 Business
AI Products Identified (Ring 1)
Immune Medicine TCR-Antigen Map (AI/ML-powered TCR-to-disease mapping)Adaptive Immunosequencing (research sequencing services using AI/ML analysis)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic test (NGS-based, not AI)MRD Pharma testing services (sequencing-based)
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix